Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.2000 (1.12%) ($7.0000 - $7.5100) on Fri. May. 24, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.18% (three month average) | RSI | 31 | Latest Price | $7.2000(1.12%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -6.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -2.59% in a week (0% probabilities). VXX(-38%) TLT(-9%) VIXM(-7%) UUP(-6%) IFRA(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.59% (StdDev 5.18%) | Hourly BBV | 0 () | Intraday Trend | 2.9% | | | |
|
Resistance Level | $7.45 | 5 Day Moving Average | $6.99(3%) | 10 Day Moving Average | $6.97(3.3%) | 20 Day Moving Average | $7.45(-3.36%) | To recent high | -15.1% | To recent low | 38.7% | Market Cap | $912m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |